信迪利单抗联合培门冬酶、吉西他滨和奥沙利铂一线治疗晚期结外NK/T细胞淋巴瘤(SPIRIT):多中心、单臂、2期试验
该多中心单臂2期试验在3个中国医学中心纳入34例初治晚期结外NK/T细胞淋巴瘤患者,接受信迪利单抗联合P-GEMOX方案(培门冬酶、吉西他滨、奥沙利铂)治疗,完全缓解率为85%(29/34,95%CI 70-94),总缓解率100%,24个月无进展生存率64%,最常见3-4级治疗相关不良事件为中性粒细胞减少(50%)。
要点
- 信迪利单抗联合P-GEMOX一线治疗晚期ENKTL的完全缓解率达85%(29/34)。
- 24个月无进展生存率64%,36个月总生存率76%。
- 最常见3-4级不良事件为中性粒细胞减少(50%)、贫血(29%)和高甘油三酯血症(29%)。
核心结论
- 信迪利单抗联合P-GEMOX似为晚期ENKTL患者有效且安全的一线方案。
研究设计与样本
- 多中心、单臂、2期试验,在中国3个医学中心开展。
- 纳入34例18-75岁初治病理确诊的晚期ENKTL患者,ECOG体能状态评分0-2分。
- 治疗方案:信迪利单抗200 mg静脉注射第1天,培门冬酶2000 U/m2肌内注射第1天,吉西他滨1 g/m2静脉注射第1天和第8天,奥沙利铂130 mg/m2静脉注射第1天,每3周一次,共6个周期;随后信迪利单抗200 mg静脉注射每3周一次,最长2年或直至疾病进展或不可接受的毒性。
- 主要终点为意向治疗人群的完全缓解率;次要终点包括总缓解率、无进展生存期、无病生存期和总生存期。
- 试验注册号ClinicalTrials.gov NCT04127227;入组已完成,随访正在进行。
主要发现
- 2019年11月29日至2022年9月7日共入组34例符合条件患者,中位年龄39岁(IQR 32-55),男性25例(74%),女性9例(26%),均为亚洲裔。
- 数据截止2023年7月20日,中位随访21个月(IQR 13-32)。
- 完全缓解率为85%(29/34,95%CI 70-94);部分缓解5例(15%,95%CI 7-30),总缓解率100%(34/34)。
- 24个月无进展生存率64%(95%CI 48-86),24个月无病生存率72%(95%CI 54-95),36个月总生存率76%(95%CI 52-100)。
- 最常见3或4级治疗相关不良事件:中性粒细胞减少17例(50%)、贫血10例(29%)、高甘油三酯血症10例(29%);甲状腺功能减退是最常见的免疫相关不良事件(18例,53%),包括1例(3%)3级甲状腺功能减退导致治疗终止;无严重不良事件发生;3例死亡(1例嗜血细胞综合征,1例疾病进展,1例原因不明),均认为与治疗无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed cell death protein 1 (PD-1) inhibitor sintilimab is effective in relapsed and refractory extranodal natural killer/T cell lymphoma (ENKTL), nasal type. We aimed to assess the safety and activity of sintilimab plus P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) in the first-line setting for advanced ENKTL. METHODS: The multicentre, single-arm, phase 2 trial was done at three medical centres in China. Patients aged 18-75 years with treatment-naive pathologically confirmed advanced ENKTL and an with Eastern Cooperative Oncology Group performance status score of 0-2 were eligible. Patients received intravenous sintilimab (200 mg on day 1), intramuscular pegaspargase (2000 U/m2 on day 1), intravenous gemcitabine (1 g/m2 on days 1 and 8), and intravenous oxaliplatin (130 mg/m2 on day 1) every 3 weeks for six cycles, followed by intravenous sintilimab (200 mg) every 3 weeks for up to 2 years or until disease progression or unacceptable toxicities. The primary endpoint was the complete response rate in the intention-to-treat population. The secondary endpoints were overall response rate (ORR), progression-free survival (PFS), disease-free survival (DFS), and overall survival. This trial is registered with ClinicalTrials.gov, NCT04127227. Enrolment has been completed, and follow-up is ongoing. FINDINGS: Between Nov 29, 2019, and Sept 7, 2022, 34 eligible patients were enrolled (median age 39 years [IQR 32-55]; 25 [74%] of 34 patients were male; nine [26%] were female; and all were of Asian ethnicity). At the data cutoff (July 20, 2023), the median follow-up was 21 months (IQR 13-32). The complete response rate was 85% (29 of 34 patients, 95% CI 70-94). Five patients (15%; 95% CI 7-30) attained partial response and the ORR was 100% (34 of 34 patients). 24-month PFS was 64% (95% CI 48-86), 24-month DFS was 72% (54-95), and 36-month overall survival was 76% (52-100). The most common grade 3 or 4 treatment-related adverse events were neutropenia (17 [50%] of 34 patients), anaemia (10 [29%] patients), and hypertriglyceridemia (10 [29%] patients). Hypothyroidism was the most frequent immune-related adverse event (18 [53%]), including grade 3 hypothyroidism in one (3%) patient that caused treatment termination. No severe adverse events occurred. There were three deaths: one due to haemophagocytic syndrome, one due to disease progression, and one due to unknown cause, which were not considered to be treatment related. INTERPRETATION: Combination of sintilimab with P-GEMOX seems to be an active and safe first-line regimen for patients with advanced ENKTL. FUNDING: National Key Research and Development Program and National Natural Science Foundation of China, Guangzhou Science and Technology Program and the Clinical Oncology Foundation of Chinese Society of Clinical Oncology.
引用
- Tian XP, Cai J, Xia Y, et al. First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2024. PMID: 38554717. doi:10.1016/S2352-3026(24)00066-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。